Ying Li1, Rui Li 1, Wenjia Liu1, Xin Lou1, and Lin Ma1
1PLA General Hospital, Beijing, People's Republic of China
Synopsis
In this crossover intra-individual comparison
study, we aimed to compare the non-ionic (godadiamide, Gd-DTPA-BMA) and ionic (gadopentetate
dimeglumine, Gd-DTPA) Gadolinium based contrast agents (GBCA) in the
quantitative evaluation of C6 glioma with dynamic contrast enhanced MR imaging
(DCE-MRI) at 3.0 T MR scanner. Ktrans, Ve and VP
maps were generated. Three radiologists independently
performed tumor segmentation and value calculation. Gd-DTPA-BMA
has significant more pixel counts of glioma in Ktrans map and
increased tendency for average Ktrans and Kep values,
indicating that DCE-MRI with Gd-DTPA-BMA may be more suitable and sensitive for
the evaluation of glioma.
Target audience
Dynamic contrast enhanced MR (DCE-MR)
is a promising technique for tumor monitoring especially for tumor treatment
evaluation. Different contrast media choice will result in different parameters
even by using same model. All the MR Magnetic resonance technicians and doctors
are the target audience of the study.Objective
This study aimed to prospectively compare the non-ionic (godadiamide, Gd-DTPA-BMA)
and ionic (gadopentetate dimeglumine, Gd-DTPA) Gadolinium
based contrast agents (GBCA) for dynamic contrast enhanced magnetic resonance
imaging (DCE-MRI)
of C6 glioma at 3.0 TeslaMethods
C6 glioma model was established in 18
Wistar rats. DCE-MRI was performed 6 days after tumor implantation with MR
(3.0 T, Discovery 750, GE healthcare, Milwaukee, USA) scans. Each
rat received two identical DCE-MRI scans with Gd-DTPA-BMA and Gd-DTPA separated
by 24 hours in randomized order. Scanning protocol was VIBRANT, including T1map
(TR 7.4 ms, TE 2.0 ms, slice gap=3, slice gap=0, matrix=160×128, FOV=12cm, Flip
angle=2 o, 3 o, 6 o, 9 o, 12 o,
15 o) and dynamic enhanced T1WI (Flip angle=12 o, the
other patameters are the same as T1map) after a bolus injection (0.2ml/s) at 0.4
mmol/kg. Image data were processed with two-compartment model. Ktrans, Ve and VP maps
were generated, and the tumors were manually segmented on all three dimensional
(3D) maps. Kep values were calculated with the values of Ktrans
and Ve. Pixel counts and mean values were recorded for paired-t test. Three radiologists who were
blind to the groups independently performed tumor segmentation and value
calculation. The agreements from different observers were subjective to intra-class
correlation coefficient (ICC).Results
Three readers demonstrated the pixel counts of tumor in Ktrans map were higher with Gd-DTPA-BMA than the counts with Gd-DTPA (P= 0.026, P=0.043, P=0.009). Although the Ktrans and Kep values were higher with Gd-DTPA-BMA than with Gd-DTPA, there were no statistical significance (P>0.05, all readers), respectively. The pixel counts and values of tumor with Gd-DTPA-BMA and Gd-DTPA in Ve map and Vp map were similar (P>0.05, all readers). Inter-observer agreement was excellent for all assessments (ICC = 0.802-0.983).Discussion
It was demonstrated in our study that DCE-MRI
apparently captures more leaky pixels by using Gd-DTPA-BMA than Gd-DTPA,
suggesting that non-ionic GBCA with low osmolarity, low viscosity, and low molecular
weight could penetrate the broken BBB easier and reveal more permeable location
in the vascular wall of the tumor. Ktrans and Kep values showed
an increased tendency with Gd-DTPA-BMA, but there were no difference between
the two GBCAs on Ve and Vp maps since Ve and Vp
represent the density of contrast agent saved in extracellular fluid and vascular
space, which are not affected by the permeability.Conclusion
Different GBCAs can
potentially influence DCE-MRI data at 3.0 T. More leaky pixel were found with Gd-DTPA-BMA
in C6 glioma model by using DCE-MRI compared with Gd-DTPA.Acknowledgements
No acknowledgement found.References
References
1. Gordon Y, Partovi S, Müller-Eschner M. Dynamic
contrast-enhanced magnetic resonance imaging: fundamentals and application to
the evaluation of the peripheral perfusion. Cardiovasc
Diagn Ther. 2014;4:147-164.
2. Bellin MF, van der Molen AJ.
Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66:van der Molen AJ, Bellin MF.
Extracellular gadolinium-based contrast media: differences in diagnostic
efficacy. Eur J Radiol. 2008;66:160-167.
3.
van der Molen AJ, Bellin MF.
Extracellular gadolinium-based contrast media: differences in diagnostic
efficacy. Eur J Radiol. 2008;66:168-174.
4. Quick A, Patel D, Hadziahmetovic M, et al.
Current therapeutic paradigms in glioblastoma.
Rev Recent Clin Trials. 2010;5:14-27.
5. Allhenn D, Boushehri MA,
Lamprecht A. Drug delivery strategies for the treatment of malignant
gliomas. Int J Pharmaceut. 2012;436:299-310.
6. Jensen RL, Mumert ML, Gillespie DL, et
al. Preoperative dynamic contrast-enhanced
MRI correlates with molecular markers of hypoxia and vascularity in specific
areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol. 2014;16:280-291.